Investor Access · Confidential
For accredited investors only · April 2026
Pre-IND · PAR4 Antagonist · Vanderbilt Spinout · $10M Seed

First-in-Class Drug &
Diagnostic for
Menopausal Thromboinflammatory
Cardiovascular Disease

SEP-001 PAR4 antagonist and ThromboRisk™ companion diagnostic — targeting the only unaddressed axis of cardiovascular risk in estrogen-deficient women.

Request Investment Deck Explore the Science
SEP-001 · PAR4 Antagonist ThromboRisk™ Panel Vanderbilt Drug Discovery April 2026 · Confidential
50M+
US Postmenopausal Women
No existing therapy addresses the thromboinflammatory axis in this population. Zero.
2×
CV Mortality Increase
Within 10 years of menopause onset. Risk inflects at perimenopause — it doesn't accumulate gradually.
3×
PAR4 PMP Drive vs PAR1
PAR4 generates 3× more platelet microparticles than PAR1 — the unaddressed thromboinflammatory driver (Hamm lab, PMID 23307185).
<5%
HRT Penetration in High-Risk Populations
Even optimal HRT cannot address PAR4-driven epigenetic changes in bone marrow megakaryocytes.
The Opportunity

Women's Cardiovascular Risk Doesn't Accumulate — It Inflects

The perimenopausal transition is a coordinated biological event. Estrogen withdrawal simultaneously elevates LDL, reduces insulin sensitivity, and activates the thromboinflammatory cascade — in a compressed window, not gradually over decades.

HRT initiated early attenuates cardiovascular risk (KEEPS, ELITE, WHI re-analyses). The problem: HRT penetration remains below 5% even in high-risk populations. And even optimal, well-timed HRT does not address the thromboinflammatory axis.

Women's heart disease is microvascular: clear arteries, microclots, and inflammation — not plaque occlusion. Existing therapies are built for the wrong model.

Key Insight
"A woman can be completely symptom-free on HRT or fezolinetant and still carry elevated PAR4-AI, elevated PMP burden, and advancing thromboinflammatory disease."
CV Disease Risk Elevation Post-Menopause
% increase vs. premenopausal baseline · conditions driven by PAR4/thromboinflammatory axis highlighted
PAR4 / Thromboinflammatory axis — addressed by SEP-001
Broader cardiovascular axis
Sources: AHA Circulation 2020; European Heart Journal 2022 (n=1.4M women); Go Red for Women / NHANES
The Treatment Landscape

Three Axes of Menopause CV Risk — One Unaddressed

Treatment Axis HRT Fezolinetant (NK3) SEP-001 (PAR4) HRT + SEP-001
CNS Symptom Relief
Hot flashes · sleep · mood · cognition
 YesYesNoYes
Peripheral Endothelial / Lipid
Vascular tone · LDL · eNOS — early window only
 PartialNoNoPartial
Peripheral Thromboinflammatory
PAR4 · microclots · PMP burden · NETosis
 NoNoYES ◆YES ◆
The thromboinflammatory axis is the only axis where NO existing therapy — hormonal or non-hormonal — provides coverage. SEP-001 addresses it directly. Every fezolinetant (Veozah) prescription creates a symptom-controlled patient with zero thromboinflammatory protection.
The Mechanism

PAR4: A Targetable, Biomarker-Identifiable
Driver of Thromboinflammation

01
Estrogen Withdrawal
Removes suppression of thrombin sensitivity; disinhibits F2RL3 methylation maintenance in bone marrow megakaryocyte progenitors.
02
F2RL3 Demethylation
Chromatin-level change in megakaryocyte progenitors — persistent and incompletely reversed by HRT. F2RL3 hypomethylation predicts CV mortality (ESTHER cohort, PMID 24510982).
03
PAR4 Upregulation
Increased PAR4 expression on platelets; elevated thrombin sensitivity; loss of estrogen-mediated platelet quiescence. Cathepsin G provides a third PAR4 activation axis.
04
PMP Storm
PAR4 drives 3× more platelet microparticle release than PAR1 via Rho-kinase/MLC axis. PMPs carry 5–100× the procoagulant activity of resting platelets (PMID 23307185).
05
Thromboinflammatory Loop
PMPs deliver P-selectin, CXCL4, CCL5 to vascular and immune cells — a self-amplifying loop that vorapaxar (PAR1 antagonism) leaves entirely intact.
3×
PAR4 PMP Drive vs PAR1
PAR4 generates 3× more platelet microparticles via Rho-kinase/MLC axis. PMPs carry 5–100× the procoagulant activity of resting platelets. This is the mechanism vorapaxar does not address.
F2RL3
Epigenetic Lock-In
Demethylation in long-lived bone marrow stem cells creates persistent thromboinflammatory risk — independent of circulating estrogen and incompletely reversed by HRT.
Vorapaxar Gap
Why PAR1 Antagonism Is Not Enough
Vorapaxar showed reduced MACE but carries bleeding liability and leaves PAR4-driven microparticle thromboinflammation intact. SEP-001 preserves PAR1-mediated hemostasis while targeting the residual PAR4 axis.
BMS Validated IP Gap
Class Safety Proven · Septagen Owns the Women's Health IP
BMS advanced PAR4 to Phase 2 — no bleeding signal. BMS externalized the program. BMS's broad PAR4 IP explicitly excludes women's health indications. Septagen filed compound + indication. We occupy the exact space BMS cannot reach.
The Therapeutic

SEP-001: Potent, Selective PAR4 Antagonist
from World-Leading Discovery Program

Vanderbilt Drug Discovery has advanced 12+ drugs to the clinic. SEP-001's benzofuran-thiadiazole scaffold is differentiated from BMS's discontinued program. Lindsley's lab is actively progressing a series of follow-on PAR4 antagonist compounds.

12+
Drugs advanced to clinic by Vanderbilt Drug Discovery
AKI
First in vivo efficacy in ischemia-reperfusion model
Pre-IND
IND-enabling studies defined and in progress
No Bleed ✓
No increase in bleeding at pharmacologically active doses
Development Progress
✓
Lead ID
✓
In Vivo
✓
PK
→
IND-Enabling
○
IND Submit
Key Pharmacokinetic Properties
~30h
Plasma Half-Life
QD
Once-Daily Dosing
High
Oral Tissue Distribution
Oral
Chronic Prevention
In Vivo Efficacy — AKI Dose-Dependent Survival
Vehicle (control)
SEP-001 1mg/kg
SEP-001 5mg/kg
p = 0.0028 (Chi-Square) · Resembles PAR4 knockout phenotype
The Diagnostic

ThromboRisk™ Panel: Revenue-Generating Companion Diagnostic

1
Genomic
F2RL3 CpG Methylation Status
CPT 81479 · 81599 · Thr120Ala PAR4 SNP
Baseline molecular risk. Identifies epigenetic lock-in and heritable PAR4 overexpression — including gain-of-function SNP in women of African descent. Establishes risk independent of HRT status.
2
Functional
PAR4 Activation Index (PAR4-AI)
CPT 85576 · Impedance aggregometry TRAP-6
Real-time platelet activation. Quantifies current thromboinflammatory activity. Confirms pharmacological target engagement — no existing assay provides this readout.
3
Burden
CD41+/PS+ PMP Burden · hsCRP · IL-6
LDT · AMA PLA pathway
Downstream disease burden. Direct measure of PAR4-driven thromboinflammation. Monitors treatment response and residual risk over time.
Why ThromboRisk™ is a Moat, Not a Feature
$7M
Pathway to commercial CLIA lab launch
2 yrs
Timeline to revenue generation
40–50%
Trial size reduction with biomarker enrichment
AMA PLA
Dedicated CPT code — next milestone
  • Companion diagnostic IP filed alongside SEP-001 — bundled asset raises acquiror switching costs and supports a 40–50% acquisition premium.
  • F2RL3 methylation as a biomarker is novel and unpublished — first-mover advantage in pharmacoepigenomics of platelet biology.
  • PAR4-AI provides a pharmacodynamic readout unavailable with any existing platelet assay — enables precision dosing and label differentiation.
  • Three-tier architecture supports independent reimbursement at each stage: screening, treatment gating, and monitoring.
  • Hamm lab postmenopausal donor platelet bank provides proprietary translational data unavailable to competitors.
Target Populations

Four High-Value Target Populations

No franchise currently targets estrogen-deficiency–driven thromboinflammation. Septagen occupies that gap and complements existing portfolios rather than displacing them.

50M+
Postmenopausal Women
Age 50–65 with CV risk factors
  • Residual CV risk despite statin / aspirin therapy
  • Elevated hsCRP and inflammatory markers
  • HRT refusal or contraindication — PAR4 is hormone-free
~500K
Surgical Menopause / POI
Abrupt estrogen withdrawal at any age
  • Earlier and more severe thromboinflammatory activation
  • Higher cumulative lifetime CV risk vs. natural menopause
  • HRT often contraindicated (thrombophilia, BRCA, VTE)
3M+
Aromatase Inhibitor Users
ER+ breast cancer survivors
  • Iatrogenic estrogen deficiency — profound and sustained
  • Known CV and thrombotic complications from AI therapy
  • Oncologists seeking cardioprotective adjunct
Growing
NK3 Antagonist Users
Fezolinetant (Veozah) · Elinzanetant
  • Symptom-controlled with zero CV protection
  • Fezolinetant FDA approved May 2023 — market accelerating
  • Every prescription is a patient SEP-001 can serve
The NK3 Tailwind: Every fezolinetant and elinzanetant prescription creates a growing population of symptom-controlled women with zero thromboinflammatory protection. Septagen is the only company positioned to serve them.
Development Strategy

Dual-Asset Strategy: Diagnostic Revenue Funds Drug Development

Current RaiseYears 1–2 · $10M Seed
Phase 1 / Proof-of-ConceptYears 3–4
Exit / PartnershipYears 5–6
Diagnostic Track
  • Launch ThromboRisk™ LDT diagnostic
  • Validate PAR4 biomarker in menopausal cohorts
  • Apply for AMA PLA dedicated CPT code
  • Finalize commercial CLIA assay
  • Confirm biomarker predicts drug response
  • Companion diagnostic partnering
  • Diagnostic revenue fully established
  • Stratify women by ThromboRisk™ Panel
Therapeutic Track
  • Complete IND-enabling safety studies
  • Manufacture clinical-grade SEP-001
  • Submit IND · Vanderbilt option-to-license
  • Phase 1 safety in 100 biomarker-selected women
  • Demonstrate PAR4 pathway engagement
  • Primary endpoint: FMD/EndoPAT
  • Proof-of-concept Phase 1/2 data package
  • Licensing or acquisition by strategic pharma
Year 2 Milestone
Revenue-generating precision diagnostic
Year 4 Milestone
Clinical-stage biotech with Phase 1 data
Target Exit
$200–$300M upfront · Post-IND/Phase 1
The Team

World-Class Team Built Around the Science

MB
Malcolm Bohm
MD, PhD · University College London
Co-Founder & CEO
Serial biopharma entrepreneur — Aspreva Pharmaceuticals, Trialytics (acquired by IMS Health), Liquid Grids (acquired by FemTec Health). Senior leadership at Novartis and Pfizer. 25+ years drug development and commercialization.
HH
Heidi E. Hamm
PhD · Vanderbilt University
Co-Founder & Chief Scientific Officer
Discovered the PAR4 thromboinflammation pathway. Endowed Chair of Cardiovascular Research, Vanderbilt University. Member, National Academy of Sciences. 360+ publications. Originating scientist behind SEP-001 and the ThromboRisk™ Panel.
Key Advisors
CL
Craig Lindsley, PhD
Medicinal Chemistry
Executive Director, Vanderbilt Drug Discovery. Advanced 12+ clinical candidates. Synthesized SEP-001 and is progressing a follow-on PAR4 antagonist series.
MO
Martin Ogletree, PhD
Pharma & Business Development
Former Bristol Myers Squibb executive. Deep cardiovascular pharma BD and licensing relationships. Expert in antiplatelet drug development.
BB
Brittany Barreto, PhD
Women's Health Strategy
Global authority in femtech and women's health innovation. Former VC. Exited women's health founder. Guides commercial positioning and investor narrative.
EW
Dr. Emma Webb
Research Scientist · Hamm Lab
Core researcher contributing to PAR4-driven platelet activation studies, PMP biology, and F2RL3 epigenetic characterization in estrogen-deficient models.
Exit Strategy

Septagen Fits the Profile of Assets Pharma Acquires Early

Nine strategic buyers with independent rationale spanning cardiovascular leaders and women's health acquirors. Target: $200–$300M upfront post-Phase 1.

AstraZeneca
CV + Women's Health
Novartis
Cardiovascular
Bayer
CV + Women's Health
Pfizer
Cardiovascular
Organon
Women's Health
Roche
Precision Medicine
Lilly
CV + Inflammation
Astellas
Women's Health
Boehringer / Takeda
Cardiovascular
Target exit: $200–$300M upfront · post-IND / Phase 1 · pre-Phase 3. Comparable to preclinical and Phase 1 cardiovascular and inflammation acquisitions 2022–2024.
Precedent Transactions
Roche × Carmot
Pre-Clinical · Metabolic therapeutic
$2.7B
Pfizer × Nimbus
Phase II · Immunotherapy
$4.0B
BMS × Nektar
Phase I · Immunotherapy partnership
$1.85B
Boehringer × Sitryx
Preclinical · Immunometabolic
$500M+
Investment Opportunity

$10M Seed Round

$11M+ in prior NIH / Vanderbilt grant funding validates the science. This raise advances Septagen to clinical stage.

$10M
Seed Round · April 2026

$10M advances Septagen to clinical stage while launching a revenue-generating companion diagnostic — the combination that transforms a pre-IND asset into an acquisition-ready platform.

Diagnostic Program
  • Validate PAR4 biomarker in postmenopausal cohort
  • Finalize commercial CLIA assay
  • Launch ThromboRisk™ LDT diagnostic
  • Apply for AMA PLA dedicated CPT code
Therapeutic Program
  • Complete IND-enabling safety studies
  • Manufacture clinical-grade SEP-001
  • Submit IND application
  • Prepare first-in-human Phase 1 trial
Request Investment Materials